Introduction
Signaling via the B-cell receptor (BCR) is thought to play a role in the pathogenesis and/or progression of chronic lymphocytic leukemia (CLL).
1,2 BCR signaling is triggered by phosphorylation of immunoreceptor tyrosine-based activation motifs of CD79a/b and induces a cascade of downstream signaling pathways. 3, 4 The importance of this cascade in CLL biology appears underscored by clinical trials demonstrating clinical activity of small-molecule kinase inhibitors that can block BCR-signaling. 5 The biology of CLL also can be influenced by microRNAs. [6] [7] [8] [9] [10] In particular, the evolutionarily-conserved microRNA miR-155 is a critical regulator of post-transcriptional gene expression in B-cells. 6 It is encoded within a region known as the B-cell integration cluster (BIC, miR155HG), which originally was identified as being a frequent integration site for avian leucosis virus.
in opposition to kinases, which are integral to many signal transduction pathways. 28 Such inhibitory phosphatases may suppress surface immunoglobulin and B-cell receptor (BCR) signaling. 29 Such signaling appears most prominent in lymph nodes (LN), where CLL cells apparently become activated in response to signals from the LN microenvironment. 30 Moreover, CLL cells in the LN have up-regulated BCR gene-expression signatures and higher proportions of cells undergoing proliferation than CLL cells in the blood. 30 Conceivably, the expression of miR-155 could influence the relative expression of SHIP1 in CLL, which then could influence the relative activation of signaling pathways triggered by ligation of the BCR by self-or environmental-antigen(s). We hypothesize that high-level expression of miR-155 in CLL can repress expression of SHIP1 and increase the responsiveness to BCR ligation, thus possibly accounting for its association with adverse clinical outcome in patients with CLL.
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Cells And Sample Preparation
Blood samples were collected from consenting patients who satisfied diagnostic criteria for CLL and enrolled in UC San Diego Moores Cancer Center biorepository, as per a protocol approved by the institutional review board (IRB) (080918). At the time of sample collection, patients had not received prior therapy. IGHV mutation status and ZAP-70 expression were assessed as per established criteria. 31 We used Ficoll-Hypaque density-gradient centrifugation to obtain mononuclear cells of which For personal use only. on July 15, 2017. by guest www.bloodjournal.org From (n=14) or used unmutated IGHV (n=10) (Figure 1B-C) .
We used an independent data set of 181 additional patients, who had expression-levels of the miR-155 precursor measured by microarray (GSE13159, GSE13164). 32 The median follow-up time for this validation cohort was 7.6 years with 64.1% (n=116) of patients receiving therapy and 24.3% patients deceased (n=44), similar to the original cohort. In the original collection of 86 samples, the mature miR-155 measured by qPCR was well correlated its precursor measured by mircroarray (r=0.6, p<0.001, Figure S4 ). We thus calibrated the cut-point established from the qPCR assay to the microarray assay using linear regression on these original 86 samples ( Figure S4 ). We then validated the association of high-level expression of miR155 (as measured by the microarray) with reduced TFS and OS in the 181 new subjects, using the optimal cut-point established through analysis on the original 86 subjects. From the analysis of these new, independent data, we observed that high-level expression of miR-155 retained its strong predictive effect for TFS ( Figure 1D ), both when considered alone (HR 1.7; 95% CI 1.1, 2.4) or in a model that contained both IGVH mutational status and ZAP-70 status (Table 2 ). In addition, greater OS was observed for the miR-155-High group, although this did not attain statistical significance in univariate analysis ( Figure S1B ). In multivariate Cox models, we confirmed the independent prognostic information of miR-155 over and above the established risk factors IGVH and ZAP-70 (Table 2) , both for TFS (HR 1.52; 95% CI 1.03 2.23) and for OS (HR 2.22; 95% CI 1.08, 4.54), using the validation cohort. Moreover, among patients with CLL cells that lacked expression of ZAP-70, those with high-levels of miR-155 (n=56) had a shorter observed median TFS (6.0 years) than patients with low-level expression of miR-155 (n = 54, 9.6 years, Figure 1E ). Among patients with CLL cells that expressed mutated IGVH genes, high-levels of miR-155 (n=48) were associated with significantly shorter median TFS (6.7 years) than those with low-level Figure 1F ).
Relationship Between High-level Expression Of miR-155 And Expression Of SHIP1 In

CLL
We examined CLL cells for expression of SHIP1 by flow cytometry. In other cell types miR-155 has been noted to target the gene encoding SHIP1, namely INPP5D.
26,27
However, miR-155 had not been reported to influence expression of SHIP1 in CLL cells. We found that CLL cells in the "High miR-155" subgroup (n=21) had a median mean fluorescence intensity ratio (MFIR) when stained for SHIP1 of 6.4 (± 0.3), which was significantly lower than that for Figure 3D ).
Intra-clonal Heterogeneity In CLL-Cell Expression Of miR-155
We interrogated the PubMed GEO database on CLL cells from lymph node (LN), bone marrow (BM) or peripheral blood (PB). We found that expression of the precursor to miR-155, namely BIC (miR155HG), was significantly greater in CLL cells isolated from LN than in CLL cells isolated from the BM or PB of the same patient ( Figure S5 ). On the other hand, the expression level of INPP5D, encoding SHIP1, appeared higher in CLL cells isolated from the blood than in CLL from the LN ( Figure S6 ). After 24 or 48 hours of stimulation, we examined for changes in expression levels of miR-155
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From and SHIP1, and in responsiveness to anti-µ. As noted for CLL cells, treatment with CD154 upregulated expression of miR-155, downregulated expression of SHIP1, and enhanced their responsiveness to BCR ligation ( Figure S8 ). We also found that CLL cells with high-levels of miR-155 also were more responsive to surface-µ ligation than CLL cells with low-levels of miR-155. Prior studies found that CLL cells that lacked ZAP-70 generally experienced lower levels of activation following treatment with anti-µ. 8, 17, 18 However, there were atypical cases that lacked expression of ZAP-70, but could be well-stimulated by treatment with anti-µ, suggesting that other factors could contribute to differences in sensitivity to BCR ligation In the present study, we examined samples that did However, CLL cells are not fixed in their anatomic distribution, but rather re-circulate between blood, lymphoid, and marrow compartments. 43 Prior studies indicated that a small proportion of CLL cells in the blood likely represent cells that have re-entered the circulation after exiting the lymphoid tissues. 33 In particular, CD5 protein, and were more sensitive to surface-µ ligation than the "resting" subgroup of blood CD5 dim CXCR4 bright CLL cells ( Figure 6 ). As such, this is the first study to define differences in the expression of miR-155 by CLL cells of the same patient and to find that this can result in functional differences in the leukemia-cells' responsiveness to BCR ligation.
We hypothesized that survival/stimulatory signals from accessory cells present in the leukemia-cell microenvironment, such as in the PCs of the LN, might contribute to the upregulation of miR-155 ( Figure 6 ). To test this hypothesis we stimulated CLL cells with CD154 or BAFF, each of which could serve to activate NF-κB. 44, 45 Prior studies found activation of NF-κB could induce expression of BIC, the precursor to miR-155. 46 However, in some B-cell lymphomas or B-cell lines (e.g. Ramos), NF-κB-induced expression of BIC did not necessarily cause increased expression of miR-155, indicating that there might be two levels of regulation for generating mature miR-155: one at the transcriptional level involving NF-κB, and one at the processing level. 46 The studies reported here demonstrate that exposure of CLL cells to factors that can activate NF-κB significantly upregulated expression of mature miR-155, suggesting that in CLL the control of miR-155 may predominately be at the level of BIC transcription.
In any case, we found that the changes induced in the expression levels of miR-155 upon treatment with CD154 or BAFF had functional significance; such treatment significantly reduced expression of SHIP1 and enhanced the responsiveness to BCR ligation, effects that could be high-levels of CD5 and low-levels of CXCR4, or low-levels of CD5 and high-levels of CXCR4.
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